Sector: MedicalAlnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
Headlines
- Alnylam Presents New Pre-clinical Data on ALN-VSP, an RNAi Therapeutic for the Treatment of Liver Cancer
Nov 18, 2009 07:00 AM | ALNY
- Alnylam Provides Update on RNAi Pipeline, Platform, and Technology at Its R&D Day
Nov 12, 2009 07:01 AM | ALNY
- Alnylam to Webcast R&D Day on Thursday, November 12, 2009
Nov 09, 2009 09:27 AM | ALNY
- Alnylam Presents New Pre-Clinical Data on RNAi Therapeutics at Oligonucleotides Therapeutics Society (OTS) Meeting
Nov 05, 2009 07:00 AM | ALNY
- Alnylam Pharmaceuticals Reports Third Quarter 2009 Financial Results
Nov 04, 2009 04:00 PM | ALNY
- Isis Pharmaceuticals to Present at the 2009 Canaccord Adams Cardiovascular Conference
Nov 03, 2009 07:01 AM | ALNY, ISIS
- Alnylam Presents New Pre-Clinical Data on ALN-TTR, an RNAi Therapeutic for the Treatment of Transthyretin-Mediated Amyloidosis
Nov 02, 2009 07:00 AM | ALNY
- Alnylam to Webcast Conference Call Discussing Third Quarter 2009 Financial Results
Oct 30, 2009 12:01 PM | ALNY
- Alnylam to Participate in Major Cardiovascular Disease Research Grant Awarded to Scientists at University of Pennsylvania
Oct 29, 2009 08:01 AM | ALNY
- Regulus Announces U.S. Allowance of Fundamental microRNA Therapeutics Patent Application
Oct 28, 2009 08:01 AM | ALNY, ISIS
- Cubist Pharmaceuticals 3rd Quarter Total Net Revenues Up 28%
Oct 15, 2009 04:51 PM | ALNY, AZN, CBST
- Alnylam Announces Allowance in Europe of New Fundamental Patent Broadly Covering RNAi Therapeutics in Oncology
Sep 09, 2009 07:56 AM | ALNY
- Alnylam and Regulus Receive Notice of Allowance from United States Patent and Trademark Office for New Patent Covering microRNA Therapeutics
Aug 11, 2009 07:12 AM | ALNY, ISIS
- Alnylam Pharmaceuticals Reports Second Quarter 2009 Financial Results
Aug 06, 2009 04:08 PM | ALNY
- Alnylam and Tekmira Participate in New Research Collaboration
Aug 06, 2009 07:13 AM | ALNY
- Alnylam to Webcast Conference Call Discussing Second Quarter 2009 Financial Results
Jul 30, 2009 05:42 PM | ALNY
- INSERTING and REPLACING Alnylam and Cubist Announce Complete Data from Phase II Study of ALN-RSV01 in Lung Transplant Patients Naturally Infected with Respiratory Syncytial Virus
Jul 20, 2009 07:52 AM | ALNY, CBST
- Alnylam and Cubist Announce Complete Data from Phase II Study of ALN-RSV01 in Lung Transplant Patients Naturally Infected with Respiratory Syncytial Virus
Jul 20, 2009 07:06 AM | ALNY
- Alnylam Announces Extension of RNAi Therapeutics Collaboration with Novartis
Jul 17, 2009 07:03 AM | ALNY
- Alnylam's Kreutzer-Limmer II Patent Upheld in European Opposition Proceedings
Jul 15, 2009 07:55 AM | ALNY
- Form 4 ALNYLAM PHARMACEUTICALS, For: Sep 09 Filed by: SCHIMMEL PAUL (10K)
Sep 11, 2009 06:01 PM
- Form 4 ALNYLAM PHARMACEUTICALS, For: Sep 04 Filed by: SCHIMMEL PAUL (10K)
Sep 09, 2009 06:14 PM
- Form 4 MARAGANORE JOHN For: Jun 16 (10K)
Jun 18, 2009 07:48 PM
- Form 4 VINCENT JAMES L For: Jun 11 (10K)
Jun 12, 2009 05:48 PM
- Form 4 SHARP PHILIP A For: Jun 11 (10K)
Jun 12, 2009 05:47 PM
- Form 4 SCOLNICK EDWARD M For: Jun 11 (10K)
Jun 12, 2009 05:47 PM
- Form 4 STARR KEVIN P For: Jun 11 (10K)
Jun 12, 2009 05:46 PM
- Form 4 ALNYLAM PHARMACEUTICALS, For: Jun 11 Filed by: SCHIMMEL PAUL (10K)
Jun 12, 2009 05:45 PM
- Form 4 DZAU VICTOR J For: Jun 11 (10K)
Jun 12, 2009 05:45 PM
- Form 4 SATO VICKI L For: Jun 11 (10K)
Jun 12, 2009 05:45 PM
Analyst Ratings
Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
Share Performance
|
Period
|
ALNY
|
Compare to S&P
|
| YTD |
-30.57 %
|
-42.65 %
|
| 4 Weeks |
-16.73 %
|
-17.17 %
|
| 12 Weeks |
-25.09 %
|
-29.70 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 60.00 %
|
|
EPS Growth in Last Year: -214.29 %
|
|
Sales Growth in Last Quarter: -1.43 %
|
|
Sales Growth in Last Quarter: -5.77 %
|
|
